|Budget Amount *help
¥24,700,000 (Direct Cost: ¥19,000,000、Indirect Cost: ¥5,700,000)
Fiscal Year 2013: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2012: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2011: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2010: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
Br-76 is an attractive positron emitter due to its long half-life (t1/2=16.1 h). In this study, Br-76-labeled amino acid derivatives were designed, and their potential as a tumor imaging agent was evaluated.
Among several Br-76-labeled amino acid derivatives, 2-[Br-76]bromo-alpha-methyl L-phenylalanine (2-[Br]-AMP) exhibited preferred pharmacokinetics and tumor accumulation in vivo. These findings suggest that 2-[Br-76]-AMP would constitute a potential new PET tracer for tumor imaging.